NIPT Developers Surprised by Illumina's Verinata Acquisition, But Say it Validates the Field | GenomeWeb

Following last week's announcement that Illumina had acquired Verinata Health in a deal worth up to $450 million, other companies that use Illumina's technology for their own noninvasive prenatal tests said the acquisition, though unexpected, ultimately validates the field.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.